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Inflammatory Airway Disease of Horses—Revised Consensus
Statement
L.L. Cou€etil, J.M. Cardwell, V. Gerber, J.-P. Lavoie, R. Leguillette, and E.A. Richard
The purpose of this manuscript is to revise and update the previous consensus statement on inflammatory airway disease
(IAD) in horses. Since 2007, a large number of scientific articles have been published on the topic and these new findings
have led to a significant evolution of our understanding of IAD.
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Horses with heaves, including those with recurrentairway obstruction (RAO) and summer pasture-
associated RAO, exhibit marked lower airway inflam-
mation and obstruction associated with frequent coughing,
increased respiratory effort at rest and exercise
intolerance.1–3 Clinical signs and airway obstruction can
be reversed by administration of corticosteroids, bron-
chodilators, or changing the environment.4–6 Recurrent
airway obstruction principally affects horses over 7 years
of age.7,8 In contrast, IAD can affect horses of all ages
and clinical signs are usually subtle, including poor per-
formance and occasional coughing but with normal
breathing at rest.9–12 Similarly, airway inflammation in
horses with IAD is mild and results in limited pulmonary
dysfunction that requires sensitive methods of detec-
tion.13–15 Both RAO and IAD are also characterized by
excessive accumulation of mucus in the airways.11,16,17
Asthma in people is characterized by a chronic airway
inflammation in patients with a history of respiratory
symptoms, such as coughing and difficulty breathing
(shortness of breath, chest tightness), which vary over
time and in intensity and are associated with expiratory
airflow limitation of variable severity.18 Recurrent air-
way obstruction (heaves) and IAD represent a spectrum
of chronic inflammatory disease of the airways in horses
resembling human asthma in many respects.19,20 There-
fore, the panel chose to use the term “equine asthma”
syndrome, as recently suggested,20 to describe these
horses with mild (IAD) to severe (RAO) airway disease
and summarized typical features of each phenotype in
Table 1. The new classification implies that horses with
similar clinical presentations (such as chronic cough,
excess mucus, poor performance) can vary widely in
terms of disease severity. However, it should not be
interpreted as a disease continuum, in which horses with
IAD necessarily develop RAO over time. Even though
individuals with mild respiratory clinical signs have an
increased risk of developing RAO,21 a transition from
IAD to RAO based on the proposed disease definitions
has not yet been reported in the peer-reviewed literature.
We recognize that the severity of airway inflammation
and remodeling observed in horses with RAO requires
time to develop. However, the majority of horses with
IAD appear to recover. There is also a subset of IAD
characterized by coughing, tracheal mucus and high tra-
cheal bacterial counts that is prevalent in racehorses in
training.22–24
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As a result, the panel proposes to define the IAD
phenotype based on clinical presentation and diagnostic
tests as follows (Table 1):
 Clinical presentation:
o Horses of any age can be affected, but IAD is
more commonly reported in young horses
o Clinical signs include poor performance and
chronic (>3 weeks), occasional coughing; if
poor performance is the only complaint, nonres-
piratory causes must be ruled out.
 Diagnostic confirmation:
o Airway endoscopy revealing excess tracheo-
bronchial mucus (score ≥2/5 for racehorses and
≥3/5 for sports/pleasure horses). Rule out other
causes of poor performance.OR
o Bronchoalveolar lavage fluid (BALF) cytology
characterized by mild increases in neutrophils,
eosinophils, and/or metachromatic cells.
o IAD diagnosis can be further confirmed for
research purposes by documenting pulmonary
dysfunction based on evidence of lower airway
obstruction, airway hyperresponsiveness, or
impaired blood gas exchange.
 We also propose the following exclusion criteria:
o Evidence of systemic signs of infection such as
anorexia, lethargy, fever, hematologic abnormal-
ities compatible with infection.
o Increased respiratory effort at rest (ie, heaves).
Clinical Signs
Racehorses and nonracehorses of all ages and from
any breed/discipline can have IAD.14,17,24–29 Clinical
signs of IAD include decreased performance and
chronic, intermittent cough.10,12,13,23 These signs are
nonspecific and can be subtle, which poses a diagnostic
challenge particularly when examining horses in the
field. Additional diagnostic tests should therefore be
considered to confirm a presumptive diagnosis of IAD
based on signs alone.
Poor racing performance in racehorses and reduced
willingness to perform in show-jumpers and dressage
horses are associated with excess tracheal mucus, but an
association with tracheal wash neutrophilia has not been
detected.10,12,30 In racehorses, poor racing performance is
associated with BALF neutrophilia.25–27,31,32 However,
poor performance is highly multifactorial and comorbidi-
ties with other respiratory and nonrespiratory conditions
in poorly performing horses must be considered.25,26,32–34
Poor performance is also difficult to define objectively,
but may be assessed based on riders’ or trainers’ impres-
sion, using semiquantitative scores.12,35,36 Signs like
delayed recovery of respiratory rate after exercise and
exaggerated respiratory effort during work,37 warrant
further consideration. Impaired pulmonary gas exchange
is a limiting factor to performance; intensely exercising
horses with IAD exhibit worsening of exercise-induced
hypoxemia,33,34,38 and lower speeds of exercise are
Table 1. Typical features of the equine asthma syndrome.
Characteristics
Equine Asthma Syndrome
IAD (Mild – Moderate Equine Asthma) RAO or SPRAO (Severe Equine Asthma)
Clinical
presentation
Age of onset Usually young to middle age but can be
observed at any age
Usually older than 7 years
Clinical signs Occasional coughing, poor performance, no
increased respiratory efforts at rest
Signs are chronic (at least 4 weeks in
duration)
Regular to frequent coughing, exercise
intolerance, increased respiratory efforts
at rest
Signs and severity may vary over time, often
limiting activity
Time course Often improve spontaneously or with
treatment. Risk of recurrence low
Typically last for weeks to months before
diagnosis. Usually improves with strict
environmental control or treatment. The
disease cannot be cured but signs can be
controlled
History Exposure to stable environment. Genetic
susceptibility has not been investigated
Exposure to dust or allergen in stable or at
pasture. Some may have a familial history of
equine asthma. Clinical signs may be seasonal
Diagnostic
confirmation
Airway endoscopy
(resting or dynamic)
Excess mucus in tracheobronchial tree
(score >1 for racehorses and >2
for sports/pleasure horses).
Rule out other differentials
Excess mucus in tracheobronchial tree
Rule out other differentials
Airway cytology Mild increase in BALF neutrophils,
eosinophils, and/or metachromatic cells
Moderate to severe increase in neutrophils
Lung function No evidence of airflow limitation based on
esophageal balloon catheter technique
(DPmax <10 cm H2O)
Airflow limitation detected using
sensitive methods
Airway hyperresponsiveness
Moderate to severe airflow limitation during
disease exacerbation based on esophageal
balloon catheter technique
(DPmax >15 cm H2O)
Reversible with bronchodilator or
environmental change
Airway hyperresponsiveness
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attained with blood lactate concentrations of 4 mmol/
L26,29; however, these variables are not specific for IAD.
Chronic cough (>3 weeks) is associated with
increased neutrophil proportions in BALF and can
therefore be used as an indicator of airway inflamma-
tion.13 Occasional coughing can also indicate an
increased risk of developing RAO.21 Cough can occur
at rest or even more frequently early during exercise,39
but the absence of reported or observed cough does not
rule out IAD.39,40 Questionnaires were found to be
effective in identifying cases of severe airway inflamma-
tion like RAO,8,39,40 whereas their usefulness for distin-
guishing IAD-affected horses from controls, based on
owner-reported clinical history, seems limited.39,40 Tho-
racic auscultation usually does not reveal abnormalities,
but some IAD-affected horses can exhibit increased
breath sounds or subtle wheezes, particularly during
rebreathing maneuvers.27,36
Serous to mucopurulent nasal discharge is commonly
observed in Thoroughbred racehorses in training,17,24
with some indication of an association between
increased nasal discharge and increased tracheal mucus
in older racehorses.22 To date, epidemiological data are
lacking for older pleasure or sport horses. The relation-
ship between nasal discharge and IAD as defined in this
revised consensus is also currently unknown. However,
similar to occasional cough, nasal discharge can indicate
an increased risk of later developing RAO.21
Pathogenesis
The pathogenesis of IAD remains incompletely
defined. A variety of etiological agents might be
involved and their relative contribution to the develop-
ment of IAD varies among different populations of
horses based on the environmental conditions they are
exposed to during and after training, feeding, housing,
season, preventive medicine practices, as well as differ-
ences in distribution of infectious agents and varying
genetic influences.41–43
Noninfectious agents are likely to be central to the
development of IAD. Horses housed in stables are
potentially exposed to high burdens of aerosolized par-
ticles and gases in a cumulative manner.44 High dust
concentrations are common in the environment of con-
ventional stables43,45–48 and several studies have identi-
fied stabling of horses as a risk factor for IAD.28,49–51
Within this environment, the respirable fraction can
contain a variety of organic and inorganic particles
including fungi, molds, endotoxin, beta-D-glucan, ultra-
fine particles (<100 nm in diameter), microorganisms,
mite debris, vegetative material, inorganic dusts, and
noxious gases.42,45,49,52,53
The relative contribution of the different environmen-
tal and stable factors to IAD is only partially known
compared to the large amount of clinical and experi-
mental evidence supporting the role of aerosolized aller-
gens and endotoxin from hay and bedding in the
etiology of RAO.44 The presence of high eosinophil or
mast cell counts, and of Th-2 cytokines such as IL-4
and IL-5, in BALF of some horses with IAD suggest a
role for aeroallergens in this syndrome.27,54 Indeed,
exposure to airborne particles has been linked to BALF
eosinophilia49 and tracheal mucus51 in young racehorses
in training. Older horses without clinical evidence of
airway disease that are exposed to high level of organic
dust and endotoxin respond with a mild to moderate
BALF neutrophilia.3,16,55 However, the role of horses’
age and exposure to particulates in the pathogenesis of
IAD phenotypes is currently unknown.
Exposure to cold, dry environments may contribute to
the pathogenesis of BALF neutrophilia in some horses
with IAD, although its role is likely to be limited.56 The
potential role of pollutants awaits further clarification.51
Inflammatory airway disease describes, by definition,
a dysregulation of the inflammatory cell homeostasis in
the airway lumen leading to clinical signs of variable
severity. Different phenotypes are recognized based on
clinical signs and age of presentation, some of which
are associated with specific inflammatory cells in
BALF.13,27 Metachromatic cells in IAD have been asso-
ciated with airway hyperreactivity and subclinical pul-
monary obstruction,13,15 whereas neutrophilic IAD has
been more often associated with cough and the presence
of tracheal mucus.11,13,57 However, these are not univer-
sal findings.25,32 It remains to be elucidated whether this
might be because of the different activities and training
methods, the effect of environmental temperatures and
conditions41,42,56 or methodological factors related to
BALF collection and analysis (see Diagnosis section).
The IAD phenotype has been associated with horses’
age in particular, BALF eosinophilia is more commonly
encountered in young horses (<5 years old)27,49, whereas
BALF neutrophilia is more frequently diagnosed in
older horses (>7 years old).13,27,39 Eosinophilic IAD is
less commonly observed, and this phenotype appears to
be related to respirable dust exposure but not internal
parasitism, in young horses.42,49 However, the implica-
tions for athletic performance are unclear. As BALF
eosinophilia has been associated with airway hyperre-
sponsiveness in horses,58 further studies are needed to
clarify eosinophil involvement in IAD pathogenesis and
its effect on performance.
Increased expression of genes encoding for TNF-a,
IL-1b, and IFN-c and protein concentrations (TNF-a
and IFN-c) have been repeatedly linked with abnormal
BALF cytology findings, both in the presence and in
the absence of clinical signs,27,59,60 suggesting that acti-
vation of the innate immune response and Th-1 polar-
ization are often involved in the pathogenesis of IAD
and most likely drive the luminal neutrophilia. Further-
more, mRNA expression of IL-17 and IL-23 have been
also linked with increases in BALF neutrophil percent-
age,54,59 and increases in IL-4 and IL-5 with the masto-
cytic form of IAD,27,54 which would support an
implication of the adaptive immune response, including
Th-2 type polarization, in some IAD phenotypes.
Interestingly, several genes related to proinflamma-
tory and stress-mediated responses, as well as to oxida-
tive balance metabolism, have been found to be
differently regulated in IAD-affected horses performing
in endurance competitions (7–12-year olds) but not in
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younger Standardbred IAD-affected horses actively rac-
ing (3–6-year olds).41 Supplementation of IAD-affected
horses with omega-3 polyunsaturated fatty acids
improved both clinical signs and BALF neutrophilia,
but a marker of oxidative stress (eg, 8-isoprostane) was
unchanged.36
The contribution of infectious agents to the develop-
ment of IAD as defined in this consensus is currently
uncertain. An association between presence of mucus
with bacteria isolated from tracheal wash (TW), espe-
cially Streptococcus zooepidemicus, and Actinobacillus/
Pasteurella species, has been reported in racehorses often
in the absence of signs of lower airway diseases.9,22,24
Increasing risk of IAD with increasing number of bacte-
rial colony-forming units per ml of TW has also been
demonstrated in racehorses.24 From these studies, how-
ever, it cannot be determined whether bacterial infections
contributed to increased mucus, or bacterial colonization
occurred as a consequence of impaired mucus clearance.
Although viral infection, especially by equine influenza
virus, is a frequent cause of transient lower airway
inflammation, the role of viral infection in IAD is still
controversial.24,61,62 Thus, there is currently no conclu-
sive evidence of a relationship between bacterial or viral
infections with IAD as defined in this consensus.
Diagnosis
The diagnosis of IAD (mild to moderate equine
asthma) is based on (1) the presence of clinical signs of
lower airway disease (poor performance, cough), (2) the
documentation of lower airway inflammation based on
excess mucus on endoscopy, BALF cytology or abnor-
mal lung function, and (3) the exclusion of severe
equine asthma (RAO/heaves) as well as infectious and
other respiratory diseases (see differential diagnoses).
Clinical Signs
Horses with IAD typically exhibit poor performance
or chronic coughing. It is important to rule out other
causes of poor performance such as upper airway
obstruction or musculoskeletal disease.
Endoscopy
A mucus scoring system has been developed to quan-
tify mucus accumulation in the trachea16: Grade 0 = no
visible mucus, Grade 1 = single to multiple small blobs
of mucus, Grade 2 = larger but nonconfluent blobs,
Grade 3 = confluent or stream forming mucus, Grade
4 = pool forming mucus, Grade 5 = profuse amounts of
mucus. Healthy horses have either no visible mucus
(grade 0) or only a few isolated specks (grade 1) evident
during tracheoscopy.26,28,63 In horses with IAD, the
amount of endoscopically visible tracheal mucus may
range from a small amount at the thoracic inlet (grade
2) to a continuous stream of variable width along the
length of the trachea (grade 3–5).11,64
Increased airway mucus (grade >1) is common in
racehorses around the world, with the highest prevalence
observed in yearlings and 2-year-old Thoroughbred
racehorses and decreasing in frequency with increasing
age (up to 4-years old)10,62,65 or time in training.17,22
Mucus accumulation is detected more frequently by
endoscopy shortly after exercise.66 Epidemiologic stud-
ies have demonstrated associations between the amount
of mucus present in the airways and coughing in Thor-
oughbred racehorses in training and older pleasure
horses22,23 as well as poor performance in racing
Standardbreds30 and Thoroughbreds10 and in sports
and dressage horses.12
The occurrence of excess tracheal mucus appears to
increase with age in pleasure horses,67 but prevalence
data in horses of all ages according to the revised IAD
consensus definition are lacking. Studies based on
convenience samples of Standardbred racehorses64 and
pleasure horses and ponies11,39 found no associations
between tracheal mucus scores and age. Clinical signs of
IAD such as excess mucus were found to last between 3
and 9 weeks on average in Thoroughbred racehorses,24,68
while signs can persist for months to years in nonrace-
horses.14 Estimates of IAD duration based on this
consensus definition remain to be further investigated.
Airway Cytology
Bronchoalveolar lavage fluid (BALF) cytology is rec-
ommended in practice to confirm a presumptive diagno-
sis of IAD based on clinical signs and airway
endoscopy. A volume between 250 and 500 mL of 0.9%
saline (physiologic or phosphate-buffered) solution
should be infused via endoscope (2-m long minimum)
or BAL tube (3-m long, 10-mm diameter).69 The larger
volume should be administered in at least 2 boluses and
suction is expected to yield between 50 and 70% of
fluid volume infused in healthy patients.
Abnormal BALF cytology is associated with poor
performance and exercise intolerance in both racehorses
and nonracehorses.26,29,31,34,70,71 Tracheal mucus accu-
mulation was found to be positively correlated with
BALF neutrophil percentage by some11 but not
others26,28,64 and negatively correlated with BALF mast
cell percentage.11
In comparison with BALF profiles from horses with
severe equine asthma (ie, RAO), which usually show
moderate to severe neutrophilia (>25% cells) and
decreased lymphocyte and alveolar macrophage
counts,14,72 BALF cytology of IAD horses is usually
characterized by mild to moderate increase in neu-
trophil, eosinophil, and/or mast cell percent-
ages.14,15,31,64,70 Cytological variations associated with
volume of fluid instilled, site of sampling, selection of
aliquot, sample preparation and cell-counting
method64,73–79 preclude the use of definitive cut-off val-
ues for the classification of IAD. However, based on
published studies that used 250-mL infusion volume,
reference values for BALF cytology in healthy controls
were: total nucleated cell count ≤530 cells/lL, neu-
trophils ≤5%, eosinophils ≤1%, and metachromatic cells
≤2%. Adjustment of BALF reference values would be
needed when using 500 mL because doubling the
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infusion volume results in lower nucleated cell count
and neutrophil percentage. Regardless of the procedure,
BALF cytology values of >10% neutrophils, >5% mast
cells and >5% eosinophils are consistent with
IAD3,26,35,37–39,54,58,59,71 and values in between are
equivocal and likely technique dependent.64,77,80 In the
end, the importance of BALF cytology should be deter-
mined in light of the history, clinical examination and
endoscopic findings.
The relationship between age and BALF cytology in
racehorses referred for poor-performance is still contro-
versial.13,25,27,32 Estimates of duration of airway inflam-
mation based on BALF are currently unknown,
however, in 1 study the majority of young racehorses
entering training had abnormal BALF cytology for at
least 4 weeks.49 As lung function was not evaluated con-
currently with BALF cytology, the significance of these
findings in relation to performance still needs to be ascer-
tained.
Historically, much research on airway inflammation in
racehorses in training has been based on TW cytol-
ogy.65,81,82 An association between TW neutrophilia and
cough23 is acknowledged, whereas the lack of an associa-
tion between TW cytology and poor performance,10 in
addition to the poor correlation between TW and BALF
cytology29,83,84 mean that TW cytology is not considered
an appropriate alternative to BALF cytology for diag-
nostic confirmation or characterization of IAD.
Clinical Pathology
Hematology variables in pleasure horses with IAD
are usually unremarkable.42,85 Racehorses presented for
poor performance may exhibit lower red cell indices
(hematocrit, hemoglobin, MCHC, MCV), but this find-
ing is not specific for IAD.26,33 Poorly performing
horses with IAD tend to exhibit impaired physiological
responses to exercise compared to healthy controls, as
evidenced by lower speed for a blood lactate of
4 mmol/L and heart rate of 160 or 200 bpm.26,29,34
Horses with eosinophilic IAD might58 or might not49
exhibit peripheral blood eosinophilia independently of
internal parasitism.
Blood Biomarkers
Various serum proteins have been evaluated for their
value in predicting abnormal BALF cytology. Serum
concentration of surfactant protein D (SP-D) in race-
horses with IAD was significantly higher than in control
horses, both at rest and after exercise.86 However, no
significant correlation was found between serum SP-D
concentrations and BALF cytology in racehorses with
IAD. Serum acute phase proteins such as serum amy-
loid A, C-reactive protein and haptoglobin do not
appear to be altered in racehorses with IAD.87,88
Lung Function
Several studies have documented the negative impact
of IAD on lung function both at rest and during
exercise. Gas exchange is impaired during exercise in
horses with IAD.33,38,89 Standard lung mechanics are
usually within reference values in racehorses with IAD
when measured at rest,14 but changes consistent with
airway obstruction can be detected using a rebreathing
method90 or by measuring airflow immediately after
strenuous exercise.91 More sensitive lung function tests
such as forced expiration and impulse oscillometry indi-
cate that horses with IAD have detectable airway
obstruction.14,15 Unfortunately, these tests are only
accessible to a handful of research laboratories.
Airway hyperresponsiveness is a prominent feature of
horses with IAD, in particular with horses that have
increased BALF eosinophil or mast cell counts.13,58,71
This test can be performed in the field and shows satis-
factory reproducibility.92 The development of bron-
choconstriction, airway hyperresponsiveness, and cough
are likely related to the airway’s response to inhaled irri-
tants and presumably play an important role in the
pathogenesis of decreased performance and impaired gas
exchange.
A practical way to discriminate RAO from IAD in
older nonracehorses is by performing a hay challenge.
Horses with IAD exposed to moldy hay may exhibit a
worsening of coughing and pulmonary neutrophilia,
but they do not develop increased respiratory efforts
or lung dysfunction at rest, as do RAO-affected
horses.14,63 This protocol is useful in the characteriza-
tion of research subjects but is not recommended for
clinical diagnosis.
Thoracic Radiographs
Radiography is another technique that, while sup-
portive of the diagnosis of IAD by exclusion of alterna-
tive diagnoses, is insufficient for diagnosis of IAD. In 1
study, a bronchial pattern was observed more fre-
quently in horses with IAD, but the sensitivity of radio-
graphy was too poor for individual diagnosis.93
Furthermore, radiographic changes were not associated
with BALF cytology or pulmonary function tests.
Differential Diagnoses
The clinical findings associated with IAD are non-
specific and shared with a diversity of other equine res-
piratory conditions. Consequently, differentiation from
other conditions is often based on the combination of
history, clinical signs, and ancillary diagnostic tests
(see Diagnosis section) and ruling out other airway
diseases.
Recurrent Airway Obstruction—Heaves
As the concept of “equine asthma” introduced above
implies, RAO (heaves) and IAD share a number of clin-
ical, cytological, and functional similarities. These simi-
larities as well as the differences between the 2
conditions are detailed in Table 1. The lack of labored
breathing at rest permits differentiation from RAO.
Also, severe exercise intolerance in RAO and a combi-
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nation of pronounced BALF neutrophilia (neutrophil
percentages >25%) and tracheal mucus accumulation
(endoscopic mucus grades >2/5) may indicate RAO. It
is important to note that within the continuum of
“equine asthma” disease processes can be dynamic.
Horses showing mild respiratory clinical signs may pro-
gress to develop RAO21; conversely, clinical signs and
laboratory abnormalities may be subtle or absent in
RAO-affected animals during periods of remission.3,94
Viral Infection
Horses with acute viral respiratory tract infections, in
particular with equine influenza virus, usually display
more severe clinical signs referable to the respiratory
tract than those with IAD as well as systemic clinical
signs. Specifically, fever, lethargy, cough, and nasal dis-
charge may be present in horses with fulminant viral
respiratory infections. Acute respiratory infections with
other viruses such as equine a-herpesvirus (EHV)-1,
EHV-4, equine rhinitis A and B or equine adenovirus
1 may be subclinical or display a milder course of
clinical signs, but are typically self-limiting.95 Equid c-
herpesvirus EHV-2 and EHV-5 are commonly identified
in respiratory secretions of horses with respiratory dis-
ease61,96 and there is limited evidence that infection with
EHV-2 is more commonly detected in horses with poor
performance and airway inflammation.61 Chronic viral
infection with EHV-5 can lead to equine multinodular
pulmonary fibrosis (EMPF), which is typically diag-
nosed in more advanced stages, when horses display
clinical signs such as increased respiratory effort and
rate as well as hypoxia at rest, pyrexia, weight loss, and
poor appetite.97,98 The presence of specific viruses in the
airways may be documented by DNA/RNA or antigen
detection (PCR, immunofluorescence), virus isolation
early in disease, or a rise in serum antibody titer over
the course of disease. However, because some viruses
(eg, EHV-2 and EHV-5) are ubiquitous both in healthy
and clinically affected horses, establishing causality is
challenging.96,97,99
Bacterial Bronchitis and Bronchopneumonia—
Pleuropneumonia
There is weak evidence for a role of bacterial bron-
chitis (caused by S. zooepidemicus or S. pneumoniae for
instance) as an etiological factor in increased tracheal
mucus or IAD, especially in young animals and horses
that have recently entered training,22,24,34,62 and differ-
entiation of bacterial bronchitis may be difficult in the
absence of systemic clinical signs or abnormal hemato-
logical variables. In contrast, manifestations of severe
infection such as fever, depression, decreased appetite,
and weight loss, typically accompanied by leukocytosis
with neutrophilia and increased immunoglobulins, are
usually present in bacterial or fungal bronchopneumo-
nia and pleuropneumonia, but are absent in IAD.
Blood work, radiographic, and ultrasonographic evalua-
tion of the chest will facilitate differentiation of these
conditions from IAD.
Lungworm Infection—Parasitic Pneumonitis
Horses with Dictyocaulus arnfieldi infection can have
clinical signs similar to those observed in IAD or
idiopathic eosinophilic pneumonia, including chronic
coughing and mucoid nasal discharge.100,101 Eosinophi-
lic inflammation in BALF is typically more severe and
persistent in parasitic pneumonitis and idiopathic eosi-
nophilic pneumonia than in eosinophilic IAD.100,102
Furthermore, direct examination of tracheal wash fluid
might reveal the presence of larvae. The parasite follows
a complete cycle in donkeys, mules, and asses but the
infection is usually not patent in horses. Therefore, the
Baermann fecal flotation is not reliable in horses. The
history of contact with donkeys and the resolution of
clinical signs with appropriate parasiticidal drugs help
differentiate lungworm infection from IAD.
Exercise-Induced Pulmonary Hemorrhage
Exercise-induced pulmonary hemorrhage (EIPH) is
common in racehorses and can be a cause of poor per-
formance.103 The diagnosis is made by finding blood
upon tracheoscopy104 or by detecting hemosiderin in
alveolar macrophages.105 Hemorrhage occurs almost
exclusively in the caudo-dorsal lung areas and is associ-
ated with macrophagic bronchiolitis and fibrosis.106 The
potential association between IAD and EIPH is contro-
versial. One study reported increased risk of EIPH with
the presence of lower airway inflammation,107 but other
studies have found no significant correlation between
hemosiderophage and neutrophil counts in BALF of
horses with IAD33 as well as no association between
EIPH and mucus score.108
Neoplasia
Thoracic neoplasia is uncommon in horses and can
present with a variety of clinical signs, some of which
might resemble IAD, in particular chronic coughing.
Bronchoscopy, thoracic radiography and ultrasonogra-
phy, and cytologic and histologic findings from biopsies
can help confirm the diagnosis and assess disease pro-
gression.
Upper Airway Diseases
Various conditions of the upper airways leading to
static and dynamic airway obstruction may cause exer-
cise intolerance and occasional coughing episodes as
observed in IAD. The presence of abnormal breathing
sounds at rest or during exercise (stridor, stertor), and
the absence of mucopurulent secretions and inflamma-
tion in the lower airways should help differentiate these
conditions from IAD, but upper airway obstruction
may occur without abnormal respiratory noise.109
Upper airway endoscopic, radiographic, and ultrasono-
graphic studies permit identification of upper airway
diseases. It is important to note that IAD and upper
airway disorders are both relatively common and con-
comitant occurrence in the same horse is therefore not
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rare. There is also some circumstantial evidence that
IAD may be more prevalent in horses with pharyngeal
dysfunction and laryngeal surgery.110,111 Conversely,
severity of upper and lower airway inflammation and
endoscopic scores were found to be independent.11
Treatment for IAD
The scientific evidence concerning the management of
horses with IAD is sparse and therapeutic choices are
mainly based on clinical experience and study results
obtained in RAO horses. Medical treatment (Tables 2
and 3) is often implemented along with management of
the environment quality and focuses mainly on decreas-
ing lung inflammation.
Control of Airway Inflammation
By analogy with RAO, where neutrophils are accu-
mulating in high number in the lower airways, horses
with IAD are often empirically treated with glucocorti-
coids. The possibility of an active infectious process
must, however, be ruled out before using immunosup-
pressive treatment.
There is only nonpeer-reviewed evidence that dexam-
ethasone and fluticasone are effective in decreasing air-
way hypersensitivity and reactivity in IAD horses and
in both cases the BAL cytology was not significantly
affected.112 The lack of decrease in BAL neutrophil
percentages after short-term glucocorticoid treatment
has also been observed in several RAO studies where
the air quality was kept unchanged.35,113,114 One study
found that long-term dexamethasone and fluticasone
treatment did not reverse the airway neutrophilia when
RAO horses are kept indoors and exposed to hay even
after 6–7 months.6 Other studies showed an additive
effect on clinical signs, airway neutrophilia, and inflam-
matory cytokines in RAO horses when combining corti-
costeroid treatment with measures to improve air
quality.6,115,116
Inhaled and systemic corticosteroids both improve
lung function in RAO horses.117 Systemic medications
commonly used to treat airway inflammation in horses
include dexamethasone and prednisolone. Systemic
treatment has the advantage of rapidly and effectively
improving clinical signs and lung function in RAO-
affected horses. It is thought that the risks of develop-
ing adverse effects associated with this treatment might
be increased compared to inhaled corticosteroids,118
although the evidence is weak. Inhaled beclomethasone
and fluticasone can be administered by metered dose
inhaler via specialized delivery devices.115,119–121 How-
ever, a fluticasone propionate metabolite was observed
in the blood and urine when the drug was administered
by inhalation at therapeutic doses,122 and adrenal sup-
pression was detected after administration of
beclomethasone dipropionate by inhalation.118
Mast cell stabilizers such as sodium cromoglycate
have been used to treat airway inflammation in
horses and improve clinical signs and decrease bron-
chial hyperresponsiveness of young racing horses with
exercise intolerance and high BALF mast cell
counts.37
Oral administration of low-dose interferon alpha (50–
150 U q24 hours, 5 days) tended to reduce neutrophilic
Table 2. Medications used systemically to treat IAD.
Medication Dosage
Frequency of
Administration
Corticosteroids
Dexamethasone 0.04 mg/kg IV or IM Once per day
0.05 mg/kg PO
Prednisolone 1.1–2.2 mg/kg PO Once per day
Bronchodilators
Aminophylline 5–13 mg/kg IV Every 12 hours
6–12 mg/kg PO
Clenbuterol 0.8–3.2 lg/kg PO Every 12 hours
Pentoxifylline 35 mg/kg PO Every 12 hours
Theophylline 5–10 mg/kg PO Every 12 hours
Other
Interferon alpha 50–150 U Every 24 hours,
5 days
Omega-3
poly-unsaturated
fatty acids
1.5 g DHA PO Once per day
for 2 months
Table 3. Medications used for aerosol treatment to treat IAD.
Drug Device Dosage Frequency of Administration
Corticosteroids
Beclomethasone Aeromask, AeroHippus, Equine Haler 1–8 lg/kg Every 12 hours
Fluticasone Aeromask, AeroHippus, Equine Haler 1–6 lg/kg Every 12 hours
Bronchodilators
Albuterol Aeromask, AeroHippus, Equine Haler 1–2 lg/kg Every 1–3 hours
Ipratropium bromide Aeromask, AeroHippus, Equine Haler 0.2–0.4 lg/kg Every 8–12 hours
Ultrasonic nebulizer 2–3 lg/kg Every 8–12 hours
0.02% solution for nebulization
Cromones
Cromolyn sodium Jet nebulizer 200 mg Every 12 hours
0.02% solution for nebulization
Ultrasonic nebulizer 80 mg Every 24 hours
0.02% solution for nebulization
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airway inflammation of racehorses with IAD and
reduced likelihood of relapse.85,123 A parallel reduction
in BALF immunoglobulins and inflammatory mediator
concentrations was demonstrated.124 Higher doses of
interferon a (450 U) appeared to be less effective. Mast
cell and eosinophil counts are not affected by interferon
treatment.
More recently, inhaled nanoparticles of cytosine–
phosphate–guanosine oligonucleotides (CpG), which
induce a Th2/Th1-shift, have been shown to decrease
neutrophil percentages in TW and mucus secretions
observed in the trachea, as well as improve lung func-
tion and clinical signs of horses with RAO.125 The rele-
vance to IAD is unknown.
Another way to modulate the inflammatory response
is by supplementing the diet with polyunsaturated
omega-3 fatty acids. A crossover study showed no
change in clinical signs in horses with RAO after chang-
ing omega 6: omega 3 fatty acid ratio with sunflower or
seal blubber oil, in spite of absorption and incorpora-
tion into leucocyte membranes.126 In another study,
supplementing the diet with omega-3 fatty acids, in par-
ticular docosahexaenoic acid (1.5 g/day for 2 months),
in addition to switching horses to a low-dust diet, was
shown to provide more rapid improvement (within 1–
2 weeks) in clinical signs of IAD and RAO when
compared to only low-dust diet (at least 4–5 weeks).36
Clinical improvement was also greater in horses
receiving docosahexaenoic acid supplementation, with
coughing being resolved in all of them by the sixth week
of treatment, whereas horses fed the low-dust diet
and placebo improved only partially and most of them
continued to exhibit occasional cough after 8 weeks.
Another controlled study tested the effects of inhala-
tion with a modified soluble curcumin derivate on RAO
horses kept in a dusty environment and found that it
decreased BAL fluid cellularity and myeloperoxidase
activity.127 Since this product targets neutrophil apopto-
sis, it might only be of interest to treat the subpopula-
tion of IAD horses with airway neutrophilia.
Bronchodilators
One of the features of IAD is airway hyperrespon-
siveness. However, the degree of bronchoconstriction is
too low to induce clinical signs at rest and has not been
well documented at rest or during exercise. Therefore,
the use of bronchodilators in IAD cases is empirical
and may not effectively improve airway patency, but
might help reduce coughing. Also, since mucus accumu-
lation is increased in the airways of IAD horses, the
increased mucociliary clearance obtained after clen-
buterol administration may be beneficial in treating
IAD.128
Treatment with bronchodilators should be done in
conjunction with measures to decrease exposure to envi-
ronmental dust so that the exposure of lower airways to
particulates is not increased. In addition, use of bron-
chodilators is probably most efficacious when combined
with corticosteroid treatment, because the underlying
mechanism of this disease is most likely related to per-
sistent airway inflammation and prolonged used of
beta-2 agonists can result in tachyphylaxis.129
Mucolytic and Mucokinetic Agents
So-called “mucoactive” treatment modalities, such as
acetylcysteine, bromhexine, ammonium chloride and
potassium iodide infusions or hyperinfusion treatment,
have been used in practice for a long time, even though
there is still little evidence for their efficacy in IAD or
RAO, and published randomized-controlled trials are
lacking.
Management and Prevention Strategies
Several approaches have been investigated to control
or prevent IAD without using pharmacological agents.
These strategies can be divided into management
changes aimed at mitigating clinical manifestations of
IAD and prevention strategies focusing on controlling
environmental triggers.
Management Strategies for IAD
There is good evidence to suggest that reducing expo-
sure to airborne dust can improve IAD clinical signs
such as coughing and poor performance.36 Two main
methods can help reduce exposure of the horse’s air-
ways to respirable particles. The first method is to use
“low dust” feedstuff and bedding that generate lower
airborne particle concentrations than hay and straw.
The second method is to increase elimination of
airborne particles and other irritants by improving
ventilation in the barn. Changing bedding from straw
to low-dust cardboard material can cut respirable dust
levels in half and reduce mold concentration to negligi-
ble levels.130 However, the most important determinant
of exposure to respirable dust is feed, especially hay53
and feeding dry hay increases the odds of having lung
inflammation in horses.39 Replacing hay feed and straw
bedding by wood shavings and a complete pelleted diet
or haylage was shown to decrease the respirable dust
burden by 2–3-fold and to decrease aeroallergen chal-
lenge.47,53 Immersing hay in water also reduces exposure
to respirable dust by approximately 60%.131 Mechanical
ventilation in stables may help decrease ultrafine parti-
cles and microorganisms (bacteria, fungi) as well as
reduce tracheal mucus score but the effect on respirable
particles and airway cytology is questionable.132
Environmental Control for Prevention of IAD
As described above, controlling exposure to dust
starts by limiting dust generation from feedstuff. Most
of the dust exposure occurs in the breathing zone dur-
ing feeding and the level of inhalation challenge is not
necessarily reflected by measurements of overall stall air
quality.47,49 For example, hay fed from a hay net will
result in greater than 4-fold increased exposure to res-
pirable dust in the breathing zone compared to feeding
the same hay on the ground regardless of background
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dust level in the stable.133 Activity in the barn and ven-
tilation affects dust exposure with peak levels occurring
during the morning or midday, especially at the time of
feeding and cleaning of the stalls.45,131 Opening of barn
doors and more open stable design, regardless of sea-
son, improve ventilation, and decrease exposure to
dust.43,49,51
Additionally, different feed and bedding materials
may have variable concentrations of endotoxin, which
can directly contribute to airway inflammation.55
Future Directions
i Determine the prevalence of the different
mild/moderate “equine asthma” phenotypes (IAD
versus RAO, based on BALF cytology) in different
equine populations.
ii Determine the relationships between coughing, tra-
cheal inflammation/infection, excess airway mucus,
lower airway obstruction, and distal airway inflam-
mation.
iii Identify systemic biomarkers of lower airway
inflammation for the diagnosis of mild/moderate
“equine asthma”.
iv Develop portable and sensitive devices to measure
lung function in the field.
v Determine the remodeling affecting the central and
peripheral airways in relation to the different phe-
notypic definitions of mild/moderate “equine
asthma”.
vi Elucidate local and systemic immune responses
associated with mild/moderate “equine asthma”
and whether they vary according to airborne stim-
uli (particulates, endotoxin, etc.) and/or the differ-
ent phenotypic subtypes.
vii Investigate the relationship between infectious
agents, based on a large and nontargeted approach
(microbiome, virome, etc.) and the development of
mild/moderate “equine asthma”.
viii Investigate possible genetic risk factors to
mild/moderate “equine asthma” (IAD) and pro-
gression to, as well as any further potential genetic
predisposition to, severe “equine asthma” (RAO)
through longitudinal and genomic studies.
ix Perform blinded, randomized, controlled trials to
determine the effect of commonly used drugs
(bronchodilators, corticosteroids, antibiotics) and
immune modulators as treatment for mild/moder-
ate “equine asthma”.
x Investigate the efficacy of environmental management
(ventilation, air purification, hay sterilization, etc.)
for controlling mild/moderate “equine asthma”.
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